Currently Viewing:
Currently Reading
Clinical Trial Participation Reduces Alcohol Intake, Improves HIV Outcomes in Women Regardless of Treatment Type
August 22, 2019 – Jaime Rosenberg
Hormone Replacement Therapy Might Place Some Menopausal Women at Increased Risk of Mortality
August 22, 2019 – Jaime Rosenberg
Results Point to Annual Assessment of Precursor to Multiple Myeloma
August 22, 2019 – Mary Caffrey
US Psoriasis Patients Face 2-Fold Mortality Risk, Study Finds
August 22, 2019 – Mary Caffrey
Air Pollution Found to Be Possible Cause of Premature Death Rates
August 22, 2019 – Matthew Gavidia
Elevated Troponin in Blood After Exercise Can Indicate Cardiovascular Disease, Study Finds
August 22, 2019 – Alison Rodriguez
What We're Reading: Gilead Challenges PrEP Patents; Opioid Addiction Treatment Use; NIH to Share Genetic Data
August 22, 2019 – AJMC Staff
More Women May Be Screened for BRCA Mutations Following USPSTF Guideline Update
August 21, 2019 – Jaime Rosenberg
MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma
August 21, 2019 – Laura Joszt

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

Mary Caffrey
Results presented at the American Heart Association in Chicago provided the strongest evidence to date on what heart failure specialists have discussed for several years now: the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes.
After the EMPA-REG OUTCOME results were announced, the DECLARE-TIMI 58 investigators decided to include 2 primary efficacy outcomes: (1) major adverse cardiovascular events, or MACE; and (2) a composite of cardiovascular death and hospitalization for heart failure. AstraZeneca had previously announced topline results for DECLARE-TIMI 58. Complete results of 17,160 patients who were followed for a median of 4.2 years found:
  • Dapagliflozin was noninferior to placebo with respect to the primary safety outcome (95% CI, <1.3; P <.001 for noninferiority).
  • For the first primary efficacy endpoint, dapagliflozin did not result in a lower rate of MACE (8.8% for the MACE group vs 9.4% in the placebo group; hazard ratio [HR], 0.93;  95% CI, 0.84 to 1.03; P = .017).
  • For the second primary efficacy endpoint, dapagliflozin did result in a lower composite rate of cardiovascular death and hospitalization for heart failure, or HHF (4.9% vs 5.8% for placebo), for a reduction of 17%. This was driven by the reduction in HHF (composite HR 0.83; 95% CI, 0.73 to 0.95; P = .005); there was no between group differences in cardiovascular death. The HR for HHF was 0.73; 95% CI, 0.61 to 0.88).
The study authors say that while they cannot rule out that differences between the drugs themselves account for the lack of a mortality benefit in DECLARE-TIMI 58, they speculated that trial design may account for this, given the drug’s mechanism of action. They note the trial had a “a more restrictive exclusion of patients according to creatinine clearance,” that could account for the difference; mortality rates were lower in the placebo group than in EMPA-REG OUTCOME, suggesting population differences.

SGLT2 inhibitors have a mechanism of action that involves blocking a protein that normally allows the body to reabsorb glucose; instead, the body discharges excess glucose through the urine, offering people with T2D glycemic control, as well as reduced blood pressure and modest weight loss. Wiviott said in the interview that besides the renal benefits, DECLARE-TIMI 58 showed no evidence of early concerns about bladder cancer—in fact, the treatment group had lower rates.

"These results are clinically relevant to the 425 million people worldwide living with diabetes, of whom those with with type 2 diabetes have a 2-to-5 times greater risk of heart failure with an increased risk of a heart attack or stroke. Heart failure survival rates are ony 50% after 5 years, which is why these new findings are so important in broadening our understanding of how to go beyond blood glucose so we may better address this serious and often overlooked cardiovascular complication," said Elizabeth Bjork, vice president, head of Cardiovascular, Renal and Metabolism, Global Medicines, Development for AstraZeneca, in a statement.

FDA recently held a 2-day hearing on the future of the cardiovascular outcomes trials, which generated the unexpected results in EMPA-REG OUTCOME and have produced the consistent results suggesting a new way forward to prevent heart failure. Asked to reflect on the value of these trials, Wiviott said based the changes to clinical guidelines the trials have already produced, it would be hard to imagine a major new class of diabetes drugs reaching the market without demonstrating cardiovascular benefits.

“It will be sorted out by the clinical community and by the market, in a sense,” he said. “One of my take-home messages about this whole area and what’s happening is that we are really moving to a place where it’s not enough to lower blood sugar—it’s how you lower it—by choosing the right agents as opposed to simply getting to a specific hemoglobin A1C target.”

Asked about the managed care benefits of using SGLT2 inhibitors and dapagliflozin, in particular, to prevent heart failure, Wiviott said that cost-benefit analyses are still needed. But with an aging population and the prospect for more patients with diabetes and congestive heart failure, there’s no question it’s important to find ways to reduce the long-term costs of these conditions.

“The concept of preventing events does have some real economic merit,” he said. “Most of the heart failure drugs we use are for treating patients with established heart failure.” Preventing heart failure in patients who don’t realize they are at risk for the disease would be a different concept, Wiviott said.

But it’s one that some heart failure specialists almost from the start of the cardiovascular outcomes trials a decade ago, when they argued that FDA should be equally focused on heart failure and not just on events like heart attacks and strokes. In an interview with AJMC® last year, Brigham and Women’s Eldrin F. Lewis, MD, MPH, said that with diabetes being the number 2 risk factor for heart disease, it’s essential to find ways to prevent heart failure in the T2D population.

“Especially in patients who have what I call the trifecta—hypertension, diabetes, and preexisting atherosclerotic cardiovascular disease—those are very high-risk populations,” he said in the interview. “Lipid lowering is important, as well, in these patients, but we need some type of precision medicine approach to managing the prevention of heart failure.”

1. Wiviott SD,  Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes [published November 10, 2018]. N Engl J Med.
2. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published online November 10, 2018]. Lancet. 2018;

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up